Exciting advancements in this field are changing the outlook for millions of healthcare patients worldwide — as well as creating lucrative opportunities for companies and investors at the front of this evolution.
New drug delivery strategies are helping convert promising therapeutics into successful therapies. As the therapeutic landscape evolves, drug delivery strategies and technologies are adapting rapidly. There are unique delivery challenges associated with the five classes of therapeutics: small molecules, monoclonal antibodies (mAbs), nucleic acids, peptides and proteins, and live cells. Each with its own risks and rewards.
PharmaBioSource can help you find, analyze and de-risk possible opportunities in this dynamic field. Whether you are a pharmaceutical company looking for new therapeutics, a CDMO looking for novel delivery platforms or financial companies looking to invest in the next big opportunity, talk with us. From acquisitions to operations, the experienced core team and global network of advisors at PharmaBioSource has a wealth of experience advising on:
- Therapeutic Asset Scouting
- Carve Outs and Divestments
- Corporate M&A transactions
- Investment Diligence
- Manufacturing Capacity Evaluation